TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22526165

Group type: EXPERIMENTAL
Intervention: Low-dose multislice-CT (MSCT) screening with five annual screens and initial quit-smoking counseling
Number of subjects: 4052

Group type: COMPARATOR
Intervention: Initial quit-smoking counseling and five annual questionnaire inquiries
Number of subjects: 4052
Study: 20164484

Group type: EXPERIMENTAL
Intervention: Low-dose platelet transfusion (1.1x10(11) platelets/m2)
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: Medium-dose platelet transfusion (2.2x10(11) platelets/m2)
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: High-dose platelet transfusion (4.4x10(11) platelets/m2)
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: Low-dose platelet transfusion
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: Platelet counts 5000 per cubic millimeter or lower
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: Platelet counts 6000 to 80,000 per cubic millimeter
Number of subjects: 1272
Study: 17085532

Group type: EXPERIMENTAL
Intervention: Resynchronisation (atrio-biventricular pacing)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Native activation (left bundle branch block)
Number of subjects: 22
Study: 15967851

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 904

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 904
Study: 12417540

Group type: EXPERIMENTAL
Intervention: TF-positive microparticles in patients with type 2 diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TF-positive microparticles from T-helper cells in patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TF-positive microparticles from granulocytes in patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TF-positive microparticles from platelets in patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microparticles from patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microparticle numbers
Number of subjects: 0
Study: 10360655

Group type: EXPERIMENTAL
Intervention: Intracavitary chemotherapy (Group A, n = 13) with weekly injection of anticancer agents (cisplatin, mitomycin‐C, adriamycin, etc.)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Immunotherapy (Group B, n = 14) with weekly injection of streptococcal preparation OK‐432
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (Group C, n = 14) with ACAs and OK‐432
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 41
Study: 8951750

Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty (BA)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Simpson Directional Atherectomy (DA)
Number of subjects: 73
Study: 1826806

Group type: EXPERIMENTAL
Intervention: Enoximone 50 mg three times a day
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Enoximone 100 mg three times a day
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 6293721

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo/Untreated
Number of subjects: 195
Study: 31586784

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg every 6 hours for 24 hours
Number of subjects: 43

Group type: COMPARATOR
Intervention: Acetaminophen 650 mg every 6 hours for 24 hours
Number of subjects: 43
Study: 27287561

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs (1470mg docosahexaenoic acid and 147mg eicosapentaenoic acid per day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 25504295

Group type: EXPERIMENTAL
Intervention: eSTI screening using a home collection kit and an e-prescription for uncomplicated treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinic-based STI screening and treatment
Number of subjects: 0
Study: 23814248

Group type: EXPERIMENTAL
Intervention: Endoscopic release
Number of subjects: 52

Group type: COMPARATOR
Intervention: Open release
Number of subjects: 52
Study: 21794114

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (perindopril)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Beta-blocker (bisoprolol)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 19802538

Group type: EXPERIMENTAL
Intervention: Chinese herbal decoction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous dripping of ganciclovir 10 mg/kg per day
Number of subjects: 60
Study: 17604311

Group type: EXPERIMENTAL
Intervention: Acupuncture for 6 weeks
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Physiotherapy for 6 weeks
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standardized advice (Control)
Number of subjects: 181
Study: 14687690

Group type: EXPERIMENTAL
Intervention: Naturalistic speech intervention (SI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phonologic speech intervention (SI)
Number of subjects: 30
Study: 11793114

Group type: EXPERIMENTAL
Intervention: Circumcision after 6 months of observation (Group 1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Circumcision immediately after the first UTI (Group 2)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Uncircumcised group (Control)
Number of subjects: 70
Study: 9597845

Group type: EXPERIMENTAL
Intervention: MOPP4-hot condition
Number of subjects: 14

Group type: COMPARATOR
Intervention: MOPP0 uniform
Number of subjects: 14

Group type: COMPARATOR
Intervention: MOPP4-cool condition
Number of subjects: 14
Study: 7932240

Group type: EXPERIMENTAL
Intervention: Voluntary hyperventilation (VHV) to 15 or 25 mmHg for 3 or 6 min with mild hyperoxic gas mixtures (inspired PO2 approximately 250 mmHg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Voluntary hyperventilation (VHV)
Number of subjects: 9
Study: 3280723

Group type: EXPERIMENTAL
Intervention: Physical endurance training (2.5 h/week for 4 months)
Number of subjects: 27
Study: 31977625

Group type: EXPERIMENTAL
Intervention: Lidocaine with magnesium sulfate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 120
Study: 29948444

Group type: EXPERIMENTAL
Intervention: LPD + KA (42 patients)
Number of subjects: 79

Group type: COMPARATOR
Intervention: LPD alone (37 patients)
Number of subjects: 79
Study: 28185808

Group type: EXPERIMENTAL
Intervention: Sled push at 75% body mass
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sled push at 125% body mass
Number of subjects: 20
Study: 25111385

Group type: COMPARATOR
Intervention: Open Prostatectomy (OP)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Bipolar Plasma Enucleation of the Prostate (BPEP)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Transurethral Resection in Saline (TURis)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Transurethral Vaporization in Saline (TUVis)
Number of subjects: 320
Study: 24138710

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen (HFNC)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 220
Study: 21419684

Group type: EXPERIMENTAL
Intervention: Post-discharge pharmaceutical care programme (verbal and written information about treatment)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard discharge without additional information (control group)
Number of subjects: 59
Study: 18328930

Group type: EXPERIMENTAL
Intervention: Doubling of cash transfers
Number of subjects: 2449
Study: 16427182

Group type: EXPERIMENTAL
Intervention: 1% NaOCl/ 30 min + EnForce
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: without 1% NaOCl + EnForce
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1% NaOCl/ 30 min + Rely X
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: without 1% NaOCl + Rely X
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study: 14632812

Group type: EXPERIMENTAL
Intervention: Dysport (283.7 U)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Botox (69.3 U)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Self-evaluation for Dysport
Number of subjects: 8

Group type: COMPARATOR
Intervention: Self-evaluation for Botox
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Local side effects for Dysport
Number of subjects: 8

Group type: COMPARATOR
Intervention: Local side effects for Botox
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Duration of positive effect for Dysport
Number of subjects: 8

Group type: COMPARATOR
Intervention: Duration of positive effect for Botox
Number of subjects: 8
Study: 11228061

Group type: EXPERIMENTAL
Intervention: GnRH agonist (n = 12)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: GnRH agonist plus COC (n = 12)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: GnRH agonist plus flutamide (n = 11)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: All groups (GnRH agonist, GnRH agonist plus COC, GnRH agonist plus flutamide)
Number of subjects: 35
Study: 8873738

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 2064943

Group type: EXPERIMENTAL
Intervention: Topical PUVA
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 6359490

Group type: EXPERIMENTAL
Intervention: 1 g metronidazole
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 2 g metronidazole
Number of subjects: 132
Study: 3903907

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease stage
Number of subjects: 0
Study: 31500524

Group type: EXPERIMENTAL
Intervention: High-dose intravenous ET-1 infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 14
Study: 30192328

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine transversus abdominis plane block
Number of subjects: 200

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 200
Study: 28116433

Group type: EXPERIMENTAL
Intervention: Lauromacrogol combined with pingyangmycin injection
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pingyangmycin injection
Number of subjects: 120
Study: 24261927

Group type: EXPERIMENTAL
Intervention: Alfredson eccentric heel-drop protocol (standard group, n = 15)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Do-as-tolerated protocol (do as tolerated group, n = 13)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison between groups at week 3
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison between groups at week 6
Number of subjects: 28

Group type: COMPARATOR
Intervention: Treatment satisfaction at week 6
Number of subjects: 28
Study: 22122475

Group type: EXPERIMENTAL
Intervention: PALS I-II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PALS I-DAS II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAS I-PALS II
Number of subjects: 0

Group type: COMPARATOR
Intervention: DAS I-II
Number of subjects: 0
Study: 19800931

Group type: EXPERIMENTAL
Intervention: Vicoprofen (hydrocodone bitartrate 7.5mg with Ibuprofen 200mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ibuprofen (200mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19164820

Group type: EXPERIMENTAL
Intervention: Lower-intensity resistance training (RTL, n = 8)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate-intensity aerobic training (ATM, n = 12)
Number of subjects: 20
Study: 15718045

Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD) subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy matched control subjects
Number of subjects: 20
Study: 14728543

Group type: EXPERIMENTAL
Intervention: Automated decision support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: On-demand decision support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10570335

Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Standard/wire-guided sphincterotome
Number of subjects: 47
Study: 8931608

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant chemotherapy
Number of subjects: 0
Study: 1881831

Group type: EXPERIMENTAL
Intervention: Verapamil (3 x 120 mg/24 hr)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6137859

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg, administered at night
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg, administered at night
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg, administered in the morning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg, administered in the morning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, administered in the morning
Number of subjects: 0
Study: 31143442

Group type: EXPERIMENTAL
Intervention: 1-day (single dose) cefazolin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-day cefazolin
Number of subjects: 0
Study: 30226448

Group type: EXPERIMENTAL
Intervention: Sitting with 3 min bouts of light‐intensity exercise while standing every 30 min
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sitting with 3 min of walking every 30 min
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sitting for 8 h uninterrupted
Number of subjects: 19
Study: 27541162

Group type: EXPERIMENTAL
Intervention: Self-expanding TAVR
Number of subjects: 383

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 383
Study: 23904473

Group type: EXPERIMENTAL
Intervention: Tocilizumab-SC 162 mg weekly
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Tocilizumab-IV 8 mg/kg every 4 weeks
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Tocilizumab-SC
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Tocilizumab-IV
Number of subjects: 1262
Study: 22512898

Group type: EXPERIMENTAL
Intervention: 54 mg OROS-MPH
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 54 mg MPH ER-C
Number of subjects: 24

Group type: COMPARATOR
Intervention: 60 mg MPH-SR
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MPH ER-C
Number of subjects: 24
Study: 20932900

Group type: EXPERIMENTAL
Intervention: Monodisperse salbutamol sulphate aerosols of 1.5, 3 and 6 μm mass median aerodynamic diameter in a cumulative dosing schedule of 10, 20, 40 and 100 μg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Monodisperse salbutamol sulphate aerosols
Number of subjects: 18
Study: 17006439

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) 1 microg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16130428

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Phenoterol
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Fixed combination of phenoterol and ipratropium bromide
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Bronchodilators (general)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: ICS-treated patients
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: ICS-untreated patients
Number of subjects: 869

Group type: COMPARATOR
Intervention: Bronchodilators
Number of subjects: 869
Study: 11495172

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral/skill training therapy (CBT)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Motivational interviewing/supportive (MIS) therapy
Number of subjects: 677

Group type: COMPARATOR
Intervention: Brief intervention (BI) treatment
Number of subjects: 677
Study: 9926240

Group type: EXPERIMENTAL
Intervention: Escalated BEACOPP
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Baseline BEACOPP
Number of subjects: 1300

Group type: COMPARATOR
Intervention: COPP/ABVD
Number of subjects: 1300
Study: 7848492

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 20
Study: 3178974

Group type: EXPERIMENTAL
Intervention: Primary closure (sutured wounds)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Leaving the wound open (unsutured wounds)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Overall infection rate
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Infection rate in hand wounds
Number of subjects: 96
Study: 1180578

Group type: EXPERIMENTAL
Intervention: End-to-end jejunoileal bypass (30 cm jejunum to 15 cm ileum)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: End-to-end jejunoileal bypass (30 cm jejunum to 20 cm ileum)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Other groups under study (not specified)
Number of subjects: 150
Study: 31520741

Group type: EXPERIMENTAL
Intervention: Immediate initiation of etoposide with antiretroviral therapy (ART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ART with delayed etoposide upon disease progression
Number of subjects: 0
Study: 28973066

Group type: EXPERIMENTAL
Intervention: Treatment Initiation and Participation Program (TIP)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 231
Study: 28039291

Group type: EXPERIMENTAL
Intervention: recombinant human thrombomodulin (rhTM)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (no anticoagulants)
Number of subjects: 92
Study: 25239474

Group type: EXPERIMENTAL
Intervention: Novel antidepressant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23061633

Group type: EXPERIMENTAL
Intervention: Clarinol™ G-80 (CLA) 2.5 ml p/d for 8 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High oleic safflower oil (HOSF) 2.5 ml p/d for 8 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 10
Study: 19401880

Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 29
Study: 17389337

Group type: EXPERIMENTAL
Intervention: Enzastaurin, taken orally once daily until disease progression or unacceptable toxicity occurred.
Number of subjects: 55
Study: 14977671

Group type: EXPERIMENTAL
Intervention: Cryotherapy device
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ice
Number of subjects: 12
Study: 14588394

Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical care
Number of subjects: 0
Study: 9291856

Group type: EXPERIMENTAL
Intervention: Auranofin 3 mg b.i.d.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 65
Study: 8438768

Group type: EXPERIMENTAL
Intervention: Zinc supplement (10 mg Zn/d as amino acid chelate) for 90.1 ± 9.2 days
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 162
Study: 2874221

Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional medical treatment (Control)
Number of subjects: 18
Study: 29431125

Group type: EXPERIMENTAL
Intervention: Virtual Trainer (VT) intervention group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (written advice of standard PA recommendation)
Number of subjects: 200
Study: 27836073

Group type: EXPERIMENTAL
Intervention: High-salt intake
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low-salt diet
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dietary salt intake
Number of subjects: 35
Study: 25028655

Group type: EXPERIMENTAL
Intervention: Pepsinogen II after H. pylori eradication
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Pepsinogen I after H. pylori eradication
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: High mononuclear infiltration in corpus
Number of subjects: 369
Study: 22690199

Group type: EXPERIMENTAL
Intervention: increased growth monitoring with feedback
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: decrease SFs and sugar sweetened beverages
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: increase FVs and low‐fat dairy
Number of subjects: 80
Study: 20830870

Group type: EXPERIMENTAL
Intervention: Limb preconditioning before induction of ischemia for surgery
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no limb preconditioning)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Limb preconditioning
Number of subjects: 34
Study: 18761242

Group type: EXPERIMENTAL
Intervention: Regional anesthesia (group 1, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anesthesia (group 2, n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 16368820

Group type: COMPARATOR
Intervention: 100 mg tramadol IV injection
Number of subjects: 20
Study: 12821954

Group type: EXPERIMENTAL
Intervention: Sodium reduction (median: -77 mmol/24 h)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (median: 44 mmol/24 h)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Sodium reduction in hypertensives
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Sodium reduction in normotensives
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Potassium supplementation in hypertensives
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Potassium supplementation in normotensives
Number of subjects: 67
Study: 10824450

Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg t.i.d.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo 5 mg t.i.d.
Number of subjects: 44
Study: 8739071

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8003236

Group type: EXPERIMENTAL
Intervention: Oral-B P-35
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crest Complete
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colgate Precision
Number of subjects: 0
Study: 3548294

Group type: EXPERIMENTAL
Intervention: Prophylactic heparin treatment (group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control nonanticoagulated group (group II)
Number of subjects: 30
Study: 31991620

Group type: EXPERIMENTAL
Intervention: Conventional application
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Co-designed application
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 30
Study: 28729040

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention for 2 years
Number of subjects: 300